Literature DB >> 24663017

Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example.

Manjunath P Pai1, Alessandro Russo2, Andrea Novelli3, Mario Venditti2, Marco Falcone4.   

Abstract

The effects of several antimicrobial agents are predicted by the ratio of the area under the concentration-time curve (AUC) to the MIC (AUC/MIC). Peak (Cp) and trough (Ct) concentrations are often measured clinically as surrogates of AUC because actual computation of AUC from 1 or 2 samples requires sophisticated mathematical methods. Given that the effects of daptomycin are predicted by AUC/MIC, our objective was to compare simple equation calculated AUC based on Cp and Ct to model integrated AUC. A standard population pharmacokinetic model was used to simulate 5,000 daptomycin concentration-time profiles after 5 doses of 6 mg/kg of body weight/day (0.5-h infusions). The AUC for the 24-h period was computed by integration and by equations with 110 Cp-Ct combination pairs. The Cp time points were in 15-min increments between 0.5 h and 3 h and Ct in 15-min increments within an hour of the end of the dosing interval for each dose. The precision and bias of the calculated AUC relative to the integrated AUC were determined to identify Cp-Ct pairs associated with the lowest bias and highest precision. The equations were further validated using two daptomycin concentration-time data sets from healthy volunteers and critically ill patients. The precision and bias of calculated AUC were based primarily on Cp, and use of a daptomycin Cp 1.5 h to 3 h from the start of infusion was associated with a bias of <10% and an R(2) of >0.95. Data from the healthy volunteers and critically ill patients also demonstrated declining bias with use of Cp ≥ 1.5 h from the start of infusion with relatively good precision. Simplified equations using a daptomycin Cp approximately 2 h from the start of infusion and a Ct within an hour of the end of the dosing interval should yield precise and unbiased estimates of daptomycin AUC.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24663017      PMCID: PMC4068499          DOI: 10.1128/AAC.02355-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock.

Authors:  Julie M Varghese; Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care Clin       Date:  2011-01       Impact factor: 3.598

2.  Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia.

Authors:  F Pea; M Crapis; P Cojutti; M Bassetti
Journal:  Infection       Date:  2013-07-25       Impact factor: 3.553

3.  TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient.

Authors:  Federico Pea; Piergiorgio Cojutti; Rodolfo Sbrojavacca; Barbara Cadeo; Francesco Cristini; Alessandro Bulfoni; Mario Furlanut
Journal:  Ann Pharmacother       Date:  2011-07-12       Impact factor: 3.154

Review 4.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

5.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

6.  A suggested approach to once-daily aminoglycoside dosing.

Authors:  E J Begg; M L Barclay; S B Duffull
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

7.  Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

Authors:  Sujata M Bhavnani; Christopher M Rubino; Paul G Ambrose; George L Drusano
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

8.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

Review 9.  Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.

Authors:  Barry I Eisenstein; Frederick B Oleson; Richard H Baltz
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

10.  Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.

Authors:  Manjunath P Pai; Jeffrey P Norenberg; Tamara Anderson; Diane W Goade; Keith A Rodvold; Robert A Telepak; Renee-Claude Mercier
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

View more
  11 in total

Review 1.  Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.

Authors:  Antonio D'Avolio; Debora Pensi; Lorena Baietto; Giovanni Pacini; Giovanni Di Perri; Francesco Giuseppe De Rosa
Journal:  Drugs       Date:  2016-08       Impact factor: 9.546

2.  The Use of Daptomycin to Treat Methicillin-Resistant Staphylococcus Epidermidis Bacteremia in a Critically Ill Child with Renal Failure.

Authors:  Stephen Morris; Kate Gould; Lee P Ferguson
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jul-Aug

3.  A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations.

Authors:  John P Prybylski
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

4.  Gap Analysis for the Conversion to Area Under the Curve Vancomycin Monitoring in a Small Rural Hospital.

Authors:  Jennifer L Cole
Journal:  Fed Pract       Date:  2020-06

5.  AUC- vs. Trough-Guided Monitoring of Vancomycin in Infants.

Authors:  Abdullah Alsultan; Manal Abouelkheir; Ahmad Albassam; Emad Alharbi; Ahmed Assiri; Saeed Alqahtani
Journal:  Indian J Pediatr       Date:  2020-01-27       Impact factor: 1.967

Review 6.  Clinical Pharmacokinetics of Daptomycin.

Authors:  Nicolas Gregoire; Alexia Chauzy; Julien Buyck; Blandine Rammaert; William Couet; Sandrine Marchand
Journal:  Clin Pharmacokinet       Date:  2020-12-14       Impact factor: 6.447

7.  Reply to: "The Possible Role of Anti-methicillin-resistant Staphylococus Aureus Antimicrobial Agents in Spontaneous Bacterial Peritonitis".

Authors:  Marco Falcone; Alessandro Russo; Manuela Merli; Mario Venditti
Journal:  Infect Dis Rep       Date:  2015-12-22

Review 8.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.

Authors:  Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts
Journal:  Intensive Care Med       Date:  2020-05-07       Impact factor: 17.440

Review 9.  Augmented Renal Clearance in Severe Infections-An Important Consideration in Vancomycin Dosing: A Narrative Review.

Authors:  Qile Xiao; Hainan Zhang; Xiaomei Wu; Jian Qu; Lixia Qin; Chunyu Wang
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

10.  Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function.

Authors:  Cornelis Smit; Anne M van Schip; Eric P A van Dongen; Roger J M Brüggemann; Matthijs L Becker; Catherijne A J Knibbe
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.